Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
WHITEHAWK THERAPEUTICS INC (WHWK)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.02-4.73%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for WHWK yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage capital through financing and M&A | A supporting condition in WHITEHAWK THERAPEUTICS INC's published investment case. The stated target is Maintain access to capital and complete strategic deals next 12 months. | Intact | Failure to secure capital or complete deals within next 12 months | Qualitative: Capital secured via $17M PIPE (May 2026) May 2026 PIPE deal closed; earnings beat in Aug 2026; no negative capital allocation events reported. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, loss-making biotechnology investment with a long-term thesis tied to clinical progress and partnerships. The thesis is on watch: management is advancing stated priorities, but recent performance trails its industry cohort and the risk label has risen to high.
WHWK is described as cheap versus peers, while the expectations gap is negative. The fragility assessment is low and judged justified, meaning weak execution quality is reflected without the full combination of expensive valuation, weak execution, and turbulence; valuation evidence has medium confidence.
Near term, cash and short-term investments have increased, extending the stated runway into the second half of 2028, and clinical enrollment is ongoing, with initial data expected in the first half of 2027. Management is on track with these priorities, though progress on pipeline partnerships is mixed; the latest earnings event was positive, while recent financial performance remains neutral and below its industry cohort.
The multi-year thesis depends on clinical progress and whether partnerships help expand the ADC pipeline, including the goal of multiple new clinical trial applications in the next 12 to 24 months. Near term, a guidance cut would be a negative signal, while continued weakness in jobs data could weigh on cyclical healthcare names; strong results and guidance from sector bellwethers would support the sector backdrop.
Over the next 1 to 3 years, WHWK’s long-term thesis has support from runway extension and ongoing development milestones, but it remains fragile because the company is loss-making, high risk, and behind its industry cohort. The main evidence to watch is clinical progress, financing runway, and whether near-term guidance and sector conditions remain supportive. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Reduce losses and improve earnings |
| A primary condition in WHITEHAWK THERAPEUTICS INC's published investment case. The stated target is EPS loss narrows toward 0 next 4 quarters. |
| Improving |
| EPS remains below -1.0 USD per share next 4 quarters |
Diluted EPS: $-0.20 per share FY2026-Q2; GAAP. Published target: EPS loss narrows toward 0 next 4 quarters. Reported actuals cannot certify a consensus target without an explicit period and accounting-basis binding. Aug 6, 2026-0.2 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Sustain revenue generation efforts | A primary condition in WHITEHAWK THERAPEUTICS INC's published investment case. The stated target is >0 USD millions revenue next 4 quarters. | Intact | revenue remains at or below 0 USD millions next 4 quarters | Revenue: $0 FY2026-Q2; GAAP. Published target: >0 USD millions revenue next 4 quarters. Target period is not explicitly aligned with this observation. Jun 30, 20260 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.19 → $-0.87 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.19 | $10,908,447 | 4 / 5 |
| 2026-07-25 | $-1.10 | $-1,142,860 | 4 / 7 |
| 2026-07-26 | $-1.10 | $-1,142,860 | 4 / 7 |
| 2026-07-27 | $-1.19 | $10,908,447 | 4 / 5 |
| 2026-07-28 | $-1.10 | $-1,142,860 | 4 / 7 |
| 2026-07-29 | $-1.19 | $10,908,447 | 4 / 5 |
| 2026-07-30 | $-1.10 | $-1,142,860 | 4 / 7 |
| 2026-07-31 | $-1.10 | $-1,142,860 | 4 / 7 |
| 2026-08-01 | $-1.19 | $10,908,447 | 4 / 2 |
| 2026-08-02 | $-1.19 | $10,908,447 | 4 / 2 |
| 2026-08-03 | $-1.10 | $-1,142,860 | 4 / 7 |
| 2026-08-04 | $-1.19 | $10,908,447 | 4 / 2 |
| 2026-08-05 | $-1.19 | $10,908,447 | 4 / 2 |
| 2026-08-06 | $-1.10 | $-1,142,860 | 4 / 7 |
| 2026-08-08 | $-1.05 | $10,908,447 | 4 / 2 |
| 2026-08-09 | $-1.05 | $10,908,447 | 4 / 2 |
| 2026-08-10 | $-1.05 | $10,908,447 | 4 / 2 |
| 2026-08-12 | $-1.05 | $10,908,447 | 4 / 2 |
| 2026-08-13 | $-0.99 | $0 | 3 / 7 |
| 2026-08-14 | $-1.05 | $10,908,447 | 4 / 2 |
| 2026-08-15 | $-1.05 | $10,908,447 | 4 / 2 |
| 2026-08-16 | $-1.05 | $10,908,447 | 4 / 2 |
| 2026-08-17 | $-1.05 | $10,908,447 | 4 / 2 |
| 2026-08-18 | $-1.05 | $10,908,447 | 4 / 2 |
| 2026-08-19 | $-1.05 | $10,908,447 | 4 / 2 |
| 2026-08-20 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-08-21 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-08-22 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-08-23 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-08-24 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-08-25 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-08-26 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-08-27 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-08-28 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-08-29 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-08-30 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-08-31 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-01 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-02 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-03 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-04 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-05 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-06 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-07 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-08 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-09 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-10 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-11 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-12 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-13 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-14 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-15 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-16 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-17 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-18 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-19 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-20 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-21 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-22 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-23 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-24 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-25 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-26 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-27 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-28 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-29 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-09-30 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-10-01 | $-0.88 | $10,908,447 | 4 / 7 |
| 2026-10-02 | $-0.89 | $10,908,447 | 4 / 7 |
| 2026-10-03 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-04 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-05 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-06 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-07 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-08 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-09 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-10 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-11 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-12 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-13 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-14 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-15 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-16 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-17 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-18 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-19 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-20 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-21 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-22 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-23 | $-0.89 | $10,908,447 | 5 / 8 |
| 2026-10-24 | $-0.87 | $10,908,447 | 5 / 8 |
| 2026-10-25 | $-0.87 | $10,908,447 | 5 / 8 |
| 2026-10-26 | $-0.87 | $10,908,447 | 5 / 8 |
| 2026-10-27 | $-0.87 | $10,908,447 | 5 / 8 |
| 2026-10-28 | $-0.87 | $10,908,447 | 5 / 8 |
| 2026-10-29 | $-0.87 | $10,908,447 | 5 / 8 |
| 2026-10-30 | $-0.87 | $10,908,447 | 5 / 8 |
| 2026-10-31 | $-0.87 | $10,908,447 | 5 / 8 |
| 2026-11-01 | $-0.87 | $10,908,447 | 5 / 8 |
| 2026-11-02 | $-0.87 | $10,908,447 | 5 / 8 |
| 2026-11-03 | $-0.87 | $10,908,447 | 5 / 8 |
| 2026-11-04 | $-0.87 | $10,908,447 | 5 / 8 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.